National Health Partners, Inc. (NHPR)
In America, there are two forcing functions driving an immediate need for reform of the U.S. healthcare. First is the large number of uninsured. Millions of citizens do not have access to primary care. In the advent of a pandemic, this situation could prove catastrophic. Also, having this many people neglecting basic care requirements may cost the economy as much as billions of dollars annually in lost productivity. And the second one High healthcare costs.
The U.S. system of health care is expensive and does not produce the best health care results. They spend a higher portion of its gross domestic product than any other country but still its ranking is low according to its performance.
National Health Partners, Inc. is a national healthcare savings organization that provides discount healthcare membership programs to uninsured and underinsured people through a national healthcare savings network called “CARExpress.” CARExpress is one of the largest networks of hospitals, doctors, dentists, pharmacists and other healthcare providers in the country and is comprised of over 1,000,000 medical professionals that belong to such PPOs as CareMark and Aetna.
National Health Partners, Inc. recently announced that it has signed a new agreement with a major marketing company that will significantly enhance the growth of its CARExpress membership base.
According to the Company, this deal, in combination with the previous partnership with Xpress Healthcare, will enable the company to build its membership base exponentially, initially generating in excess of an additional 2,000 new members per month. The new campaign is set to launch within the next few weeks and will provide a material positive impact on the company’s 2nd quarter sales.
National Health Partners anticipate that this new marketing agreement will provide a major impact on their overall sales not only for the 2nd quarter, but more importantly for the year. They look forward to building on the profits that they anticipate generating in 2011 that will be driven by substantial growth in sales of their CARExpress health discount programs. The combination of their substantial growth with their low price-to-equity ratio should reflect itself in the price of their stock over the coming months.
For more information about National Health Partners, Inc visit its website www.nationalhealthpartners.com
VCA Antech Inc. (Nasdaq:WOOF) will report financial results for its first quarter of 2011 on Thursday, April 28, 2011 at 4:00 p.m. EDT. The company will host a conference call and Webcast beginning at 4:30 p.m. EDT on that day. The Webcast can be accessed by visiting the company’s website at http://investor.vcaantech.com. Replay of the Webcast will be available for ninety days by visiting the company’s website. The conference call dial-in number is (877) 293-5492. Interested parties should call at least ten minutes prior to the conference call to register.
VCA Antech, Inc. operates as an animal healthcare company in the United States and Canada. The company offers veterinary services and diagnostic testing to support veterinary care; and sells diagnostic imaging equipment, and other medical technology products and related services to the veterinary market.
PAETEC Holding Corp. (Nasdaq:PAET) announced that its 2011 Annual Stockholders’ Meeting will be held at 9:30 a.m. ET on Thursday, June 2, 2011 at the headquarters of SAP Americas located at 3999 West Chester Pike, Newtown Square, PA 19073.
PAETEC Holding Corp., through its subsidiaries, provides integrated communications services to business and institutional customers primarily in the United States.
Endologix Inc. (Nasdaq:ELGX) announced financial results for the three months ended March 31, 2011. John McDermott, Endologix President and Chief Executive Officer, said, “First quarter revenue grew by 28% year-over-year, reflecting our continued momentum in the marketplace as the innovation leader in the endovascular treatment of abdominal aortic aneurysms (AAA). Our expanded sales force is successfully driving adoption of our products with existing customers and introducing the benefits of anatomical fixation to new customers. We also expect to launch our new AFX� Endovascular AAA System during the second half of the year, which will provide another important growth opportunity. Accordingly, we are reiterating our full year 2011 revenue guidance of $78 million to $82 million.”
Endologix, Inc. develops, manufactures, markets, and sells minimally invasive treatments for aortic disorders. Its flagship product, the Powerlink System, is an endovascular stent graft for the treatment of abdominal aortic aneurysms, a weakening of the wall of the aorta, an artery in the body.
No comments:
Post a Comment